Alibrex: A New Blood Test to Reveal Whether a Cancer Treatment is Working lundberginstitute.org/?p=157…
Tom Stitt retweeted
New blog post: Molecular Diagnostics: A Broken Business Model or Flawed Execution? link.medium.com/xuPijvAzI5 #cancer #cancertherapymonitoring #diagnostics
Could be #justinmice - not smart enough to be sure. sciencedaily.com/releases/20…
Tom Stitt retweeted
The Case for Real-Time Cancer Therapy Monitoring - Rapid identification of late-stage cancer patients who are not responding to drug therapy.
medium.com/@cadexgenomics/th…
Tom Stitt retweeted
Cadex Genomics provides real-time insight into therapy response for patients with stage IV solid tumors. “So far, Cadex’s technology is proving to be a game-changer for patients and their oncologists,” said Weiland.
medcitynews.com/2019/04/the-…
#cfDNA #cancertherapy
Tom Stitt retweeted
The doctor becomes the patient.
greenvillejournal.com/2019/0…
Tom Stitt retweeted
Cadex Genomics has been selected as a finalist in the Diagnostics category for the Pitch Perfect Startup Contest at the MedCity INVEST Event April 23-24 in Chicago, IL. cadexgenomics.com/news/5b2b7…
Tom Stitt retweeted
.@CadexGenomics’ founders, Bill Haack, Sudhir Sinha, Gary Spitzer and Greg Schafer, are creating cutting-edge tests to track #cancer patients’ therapy response. Check out how this stellar #startup team is revolutionizing diagnostics! bit.ly/2HYJ8Hz
Tom Stitt retweeted
Great to see Bay Area member @CadexGenomics presenting their Alibrex technology at our #Biocompartnering conference.
Tom Stitt retweeted
Landmark #TAILORx results demonstrate that the #Oncotype DX test identifies the 70% of women with early-stage #breastcancer who receive no benefit from chemo. Watch this video to learn more about the trial: youtube.com/watch?v=iucCGlpA…
Tom Stitt retweeted
This startup is focused on developing a #liquidbiopsy-based test to elucidate how patients may respond to certain #cancer therapies @CadexGenomics
goo.gl/APzU4s
Tom Stitt retweeted
Liquid biopsies can accurately track lung cancer treatment responses by measuring ctDNA during immunotherapy and related treatments – 2 @HopkinsKimmel studies hopkinsmedicine.org/news/new… via @HopkinsMedNews
Tom Stitt retweeted
"There is a growing need to match mutational analysis assays with a mutation agnostic diagnostic assay that can more rapidly guide and inform cancer therapy for a wide range of patients" @skopetz #cancer #diagnostic goo.gl/zGefWE
"Video Of The Week: Is Crypto the Future of Early Stage Funding?" avc.com/2018/02/video-of-the… #2.1health #feedly
Last thoughts. The journey will continue - IOHT, AI, CRISPR, genetic therapies and more will all benefit from passionate people sharing informed views on social media. #hcsm
T3 Most significant change I've seen in health/social media is lots of VC-funded direct to patient/consumer services, labs, apps, care offers aimed at healthy people. The next change I hope to see is more focus on chronic disease mgmt. #hcsm












